Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16764472 | 0.93 | JAK3 (0.34) | JAK3EGFRLCKDPP4ALDH1A1 | |
| SCHEMBL20854587 | 0.78 | PREP (0.48) | — | |
| SCHEMBL20986846 | 0.76 | MEN1 (0.39) | DPP4ALDH1A1 | |
| SCHEMBL16764831 | 0.75 | ALDH1A1 (0.33) | DPP4DPP8ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23573048 | 0.74 | RIPK1 (0.33) | JAK3LCKDPP4 | |
| SCHEMBL20854589 | 0.74 | KCNH2 (0.41) | SMN1; SMN2 | |
| SCHEMBL29145752 | 0.72 | NPY5R (0.36) | JAK3EGFRLCKNPY5RDPP4 | |
| SCHEMBL20986527 | 0.72 | NPY5R (0.36) | JAK3EGFRLCKNPY5RDPP4 | |
| SCHEMBL13455158 | 0.68 | NPY5R (0.43) | NPY5R | |
| SCHEMBL401875 | 0.68 | NPY5R (0.47) | JAK3EGFRLCKNPY5RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| US-9656988-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2016-12-08 | — | — | US | disclosed |
| EP-3077388-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, LLC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015084998-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 53/4885EGFR 692/4885LCK 3/4885 |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 60/4885EGFR 700/4885LCK 3/4885 |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 60/4885EGFR 700/4885LCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.